Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMPLIFIED Study: Mobile same-day test and treat model for excluded populations with HIV
2021-005546-15Phase 4Active
- Sponsor
- Gilead Sciences
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS), sponsored by Gilead Sciences. Started Dec 2021; status: active.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on 2021-005546-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005546-15.